Company Overview

Lasa Supergenerics Limited was incorporated on March 11, 2016, and has established itself as a prominent player in India's veterinary active pharmaceutical ingredients (API) manufacturing sector. Lasa Supergenerics Limited is an India-based veterinary active pharmaceutical ingredients (API) manufacturing company that has carved out a significant position in the specialized healthcare market.

The company operates as a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain - from discovery to delivery, with established credentials in research, manufacturing, and global marketing. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, and treating chemicals, APIs, Pharmaceuticals, drugs, etc. This comprehensive approach allows Lasa Supergenerics to maintain control over its entire production process and ensure quality standards throughout.

Business Operations and Manufacturing Capabilities

The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra, strategically positioned to serve both domestic and international markets. It specialises in `catalyst chemistry` and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. This specialization in catalyst chemistry gives the company a competitive edge in producing complex pharmaceutical compounds.

The company's manufacturing philosophy centers on backward integration, as the Company is fully backward integrated for its key molecules - from discovery research up to full-scale bulk production. This integration strategy helps maintain supply chain efficiency and cost control while ensuring consistent product quality.

Product Portfolio

Lasa Supergenerics offers a diverse range of products across multiple categories. The Company's products include API products, other API products, animal feed ingredients, and reagents for therapeutic use. The API product portfolio is extensive, including Albendazole, Fenbendazole, Oxfendazole, Povidone Iodine, Nitroxylene, Ricobendazole, Halquinol, and others.

In the animal nutrition segment, its animal feed ingredients include potassium iodide, cobalt sulfate, sodium selenate, ethylenediamine dihydroiodide, and vanadyl sulfate. The therapeutic reagents category comprises cetylpyridinium chloride, bismuth subsalicylate, and sodium selenite, demonstrating the company's broad technical capabilities across different pharmaceutical applications.

Financial Performance and Market Position

- Market Cap: ₹56.0 Cr (as per recent data)

- Recent Profitability: Net profit jumped 476.03% year-on-year to ₹5.49 Cr in Q3 FY2024-2025, indicating significant volatility in earnings performance.

- Key Financial Metrics (as of July 2025):

- PE Ratio: 62.78

- PB Ratio: 1.51

- EBITDA: ₹112.84 M

- EBITDA Margin: 4.40%

- Debt: The company maintains a relatively healthy balance sheet structure, being almost debt-free, which provides financial flexibility for future growth initiatives.

Stock Performance and Trading Information

Lasa Supergenerics is listed and trades on the NSE stock exchange under the ticker symbol "LASA." The stock has experienced significant volatility over the past year.

- 52-Week High: ₹33.49

- 52-Week Low: ₹8.52

- Recent Trends:

- Over the past 6 months, the Lasa Supergenerics share price has decreased by 56.71%.

- In the last one year, it has decreased by 51.52%.

This performance reflects broader market conditions and company-specific factors affecting the pharmaceutical sector.

Leadership and Corporate Governance

- Chairman & Managing Director: Omkar Pravin Herlekar

- Promoter Holding: 53.6% demonstrates strong promoter commitment to the business, which typically indicates management's confidence in the company's long-term prospects and strategic direction.

The management team brings experience in pharmaceutical manufacturing and has guided the company through its growth phase since incorporation.

Industry Position and Future Outlook

Lasa Supergenerics operates in the specialized veterinary pharmaceutical sector, which presents both opportunities and challenges. Lasa Supergenerics Ltd operates in Healthcare / Drug Manufacturers - Specialty & Generic, positioning it within the broader pharmaceutical industry while maintaining focus on its veterinary specialization.

The company's emphasis on catalyst chemistry and anthelmintic products positions it well to serve the growing demand for veterinary healthcare solutions. With its integrated manufacturing capabilities and established product portfolio, Lasa Supergenerics is positioned to capitalize on the expanding animal healthcare market, though recent financial performance suggests the need for strategic improvements to enhance profitability and market position.